By Foo Yun Chee BRUSSELS (Reuters) – A European court will decide on July 13 whether U.S. life sciences company Illumina’s $8 billion cash-and-stock takeover of Grail should be scrutinised by EU antitrust regulators, people familiar with the matter said on Wednesday. The case coincides with the European Commission seeking to expand its power to examine big companies’ acquisitions of start-ups aimed at shutting down nascent rivals, with the focus on tech and pharma deals. Critics call it a power grab that has even worried some national competition agencies. The Luxembourg-based General Court, E…